Nuvectis Pharma, Inc. Stock Price, News & Analysis

Nuvectis Pharma reported its Q1 2025 financial results and business updates. The company presented promising NXP900 Phase 1a clinical data at AACR 2025, showing robust pharmacodynamic response and acceptable safety in advanced cancer patients. Nuvectis completed a $15.5M financing, extending cash runway into Q1 2027. Financial highlights include: cash position of $29.9M as of March 31, 2025 (up from $18.5M in December 2024), and a net loss of $5.3M (vs $4.2M in Q1 2024). R&D expenses were $3.7M, while G&A expenses reached $1.9M. The company is preparing for NXP900's Phase 1b study and continues enrollment in the NXP800 Phase 1b trial for platinum-resistant, ARID1a mutated ovarian cancer, with updates expected in the coming months.

Nuvectis Pharma presented key findings for their cancer drug NXP900 at the 2025 AACR Meeting. The Phase 1a dose-escalation study, involving 29 patients with advanced cancers, demonstrated promising results with doses up to 250 mg/day showing an acceptable safety profile.

Key highlights:

• Treatment achieved robust pharmacodynamic responses at tolerated doses
• SRC inhibition exceeded 90% after a single dose
• Most side effects were Grade 1-2, including fatigue and nausea
• Median patient age was 62 years, with 62% males

Three preclinical posters revealed NXP900's potential in NSCLC (non-small cell lung cancer), both as a single agent and in combination with existing therapies. The company plans to commence Phase 1b trials targeting patients with YES1 gene amplifications and hippo pathway alterations, as well as exploring combinations with market-leading therapies for resistant NSCLC.

Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company specializing in precision medicines for oncology, has announced upcoming presentations for their product NXP900 at the 2025 American Association for Cancer Research Meeting (AACR). The conference will be held from April 25th to April 30th in Chicago, IL. The company focuses on developing innovative treatments for serious unmet medical needs in cancer treatment.

Nuvectis Pharma (NVCT), a biopharmaceutical company specializing in precision medicines for oncology, has announced its participation in the upcoming 37th Annual Roth Conference. The event will take place from March 17th-19th in Dana Point, California, where Ron Bentsur, Chairman and Chief Executive Officer, will engage in a fireside chat discussion.

The conference participation highlights Nuvectis's continued engagement with the investment community and its focus on developing innovative treatments for serious unmet medical needs in cancer therapy.

Nuvectis Pharma (NASDAQ: NVCT) has announced new research findings from the Cleveland Clinic demonstrating enhanced efficacy when combining their drug NXP900 with osimertinib (Tagrisso®) in treating EGFR-mutated non-small cell lung cancer (NSCLC).

The study, published in Molecular Cancer Research (2025), showed that the combination therapy was superior to osimertinib alone in vivo, resulting in decreased cell proliferation and increased apoptosis in vitro. This research validates previous findings from AstraZeneca showing NXP900's ability to reverse osimertinib resistance in resistant cell lines.

The company is approaching completion of its Phase 1a dose escalation study for NXP900 and plans to initiate a Phase 1b program, exploring opportunities both as a standalone treatment and in combination with existing anti-cancer medications.

Nuvectis Pharma (NASDAQ: NVCT) reported its 2024 financial results and business highlights, showing progress in its clinical-stage oncology drug candidates. The company's NXP800 received Orphan Drug Designation from the FDA for ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. A Phase 1b study in platinum-resistant, ARID1a-mutated ovarian cancer continues with updated results expected in Q2 2025.

For NXP900, the Phase 1a dose escalation study is ongoing with preparations underway for Phase 1b trials starting mid-2025. The upcoming program will evaluate NXP900 as monotherapy in YES1/SRC-driven solid tumors and in combination with EGFR and ALK inhibitors for non-small cell lung cancer.

Financially, Nuvectis completed a follow-on offering in February 2025, raising $15.5 million in gross proceeds, extending cash runway into 2027. The company reported a net loss of $19.0 million for 2024, compared to $22.3 million in 2023, a $3.3 million improvement. Cash and equivalents stood at $18.5 million as of December 31, 2024, slightly down from $19.1 million at the end of 2023.

Nuvectis Pharma (NVCT) has successfully closed its previously announced public offering, raising $15.5 million in gross proceeds. The offering consisted of 2,700,000 shares of common stock at $5.00 per share, along with the full exercise of the underwriter's over-allotment option for an additional 405,000 shares.

Lucid Capital Markets served as the sole book runner for the offering. The company plans to use the net proceeds to advance the development programs of NXP800 and NXP900, hire additional personnel, fund capital expenditures, cover public company operating costs, and other general corporate purposes. The offering was conducted under Nuvectis's shelf registration statement on Form S-3.

Nuvectis Pharma (NASDAQ: NVCT) has announced the pricing of its public offering of 2,700,000 shares of common stock at $5.00 per share, expecting to raise gross proceeds of $13.5 million. The company has granted the underwriter a 30-day option to purchase up to 405,000 additional shares at the same price.

The offering is expected to close on February 6, 2025, with Lucid Capital Markets acting as the sole book runner. The proceeds will be used to advance development programs of NXP800 and NXP900, hire additional personnel, cover capital expenditures, operating costs as a public company, and other general corporate purposes.

The offering is being made pursuant to Nuvectis's shelf registration statement on Form S-3, which was declared effective by the SEC on March 29, 2023.

Nuvectis Pharma (NVCT) has announced the commencement of an underwritten public offering of its common stock. The clinical-stage biopharmaceutical company, focused on developing precision medicines for oncology, will be the sole provider of all shares in the offering. Lucid Capital Markets is acting as the sole book runner.

The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of the offered shares. The net proceeds will fund the development of NXP800 and NXP900 programs, personnel hiring, capital expenditures, public company operating costs, and general corporate purposes.

The offering is being made pursuant to a shelf registration statement (File No. 333-270657) declared effective by the SEC on March 29, 2023. The completion, size, and terms of the offering are subject to market conditions.